18A.01
For the purposes of this Chapter unless otherwise stated or the context otherwise requires following terms have the meanings set out below:—
| "Approved Product" | a Biotech Product which has been approved for commercialisation by a Competent Authority. |
| "Biotech" | the application of science and technology to produce commercial products with a medical or other biological application. |
| "Biotech Company" | A company primarily engaged in the research and development, application and commercialisation of Biotech Products. |
| "Biotech Product" | Biotech products, processes or technologies |
| "Competent Authority" |
the US Food and Drug Administration, the China Food and Drug Administration, the European Medicines Agency. The Exchange may, at its discretion, recognise another national or supranational authority as a Competent Authority for the purposes of this Chapter in individual cases (depending on the nature of the Biotech Product). |
| "Core Product" | A Regulated Product that (alone or together with other Regulated Products) forms the basis of a Biotech Company's listing application under this chapter. |
| "Cornerstone Investor" | An investor in the initial public offering of a new applicant's shares to whom offer shares are preferentially placed with a guaranteed allocation irrespective of the final offer price, usually for the purpose of signifying that the investor has confidence in the financial condition and future prospects of the new applicant. |
| "Regulated Product" | A Biotech Product that is required by applicable laws, rules or regulations to be evaluated and approved by a Competent Authority based on data derived from clinical trials (i.e. on human subjects) before it could be marketed and sold in the market regulated by that Competent Authority. |